Ascending Cholangitis (Adult)

1. Overview

Ascending Cholangitis is a life-threatening bacterial infection of the biliary tree, classically occurring in the setting of biliary stasis due to obstruction. It represents one of the few true "surgical emergencies" where mechanical intervention (drainage) is as critical as pharmacological management (antibiotics). [1]

The clinical signature is defined by Charcot's Triad (Fever, RUQ Pain, Jaundice) and, in more severe cases, Reynolds' Pentad (adding Hypotension and Altered Mental Status). The pathophysiology is fundamentally rooted in the rise of intra-biliary pressure, which facilitates the translocation of enteric bacteria into the systemic circulation (Biliary-Venous Reflux). [2]

Management is strictly governed by the Tokyo Guidelines (TG18), which stratify severity and dictate the timing of biliary decompression. The gold standard for both diagnosis and therapy remains ERCP (Endoscopic Retrograde Cholangiopancreatography), which must be performed within 24–48 hours for most patients, and emergently for those in shock. [3]

Historical Context

The modern understanding of cholangitis was revolutionized by the work of Jean-Martin Charcot in 1877, who described the classic triad of fever, jaundice, and right upper quadrant pain. Subsequently, Reynolds and Dargan in 1959 expanded this to include hypotension and altered mental status in severe cases, defining what is now known as Reynolds' Pentad. The pre-endoscopic era saw mortality rates approaching 50%, but the introduction of ERCP in the 1970s and refinement of critical care protocols have reduced this to 5-10% in modern series. [4]

Key Clinical Pearls

• Cholangitis should be considered in any patient presenting with jaundice and fever, even in the absence of abdominal pain
• The absence of dilated ducts on ultrasound does NOT exclude the diagnosis
• Early biliary decompression is more important than antibiotic choice in severe disease
• Post-procedural cholangitis can occur even with prophylactic antibiotics

---

2. Epidemiology

Global Burden

Ascending cholangitis accounts for approximately 2-3% of emergency surgical admissions in developed countries. The incidence varies geographically, with higher rates in East Asia due to endemic parasitic infections (Clonorchis sinensis, Opisthorchis viverrini) and recurrent pyogenic cholangitis syndrome. [5]

Demographics and Risk Factors

Age Distribution:

• Bimodal pattern: Young adults (20-40 years) with congenital abnormalities or parasitic infections
• Elderly (> 70 years) with choledocholithiasis, representing the majority of cases in Western countries

Sex Distribution:

• Female predominance (2:1) in gallstone-related cholangitis
• Equal distribution in malignant obstruction and post-procedural cases

Etiology-Specific Incidence

Mortality Data

Overall Mortality:

• Pre-ERCP era: 40-50%
• Modern era (with ERCP): 5-10%
• Reynolds' Pentad (severe): 20-30% despite optimal management [6]

Prognostic Factors:

• Age > 75 years
• Delayed biliary drainage (> 48 hours)
• Multi-organ dysfunction at presentation
• Polymicrobial bacteremia
• Malignant obstruction

---

3. Aetiology & Pathophysiology

The Fundamental Requirement: Obstruction + Infection

Cholangitis is fundamentally a two-hit disease requiring both biliary obstruction (causing stasis) and bacterial contamination. Unlike spontaneous bacterial peritonitis where infection can occur without mechanical obstruction, the biliary tree has robust defense mechanisms that prevent infection under normal flow conditions.

The 7-Step Molecular Mechanism

Step 1: Biliary Obstruction

A mechanical obstruction (stone, stricture, tumor, or stent occlusion) blocks bile flow in the common bile duct. Bile becomes stagnant, losing its natural bactericidal properties (bile salts, IgA secretion, and mechanical clearance).

Normal Biliary Pressure: 7-14 cm H₂O
Obstructed State: Pressure rises progressively, eventually exceeding 20 cm H₂O

Step 2: Loss of Sterility

The normal biliary tree is sterile in 90% of healthy individuals. However, obstruction allows retrograde bacterial ascent from the duodenum through the ampulla of Vater. The sphincter of Oddi, which normally prevents reflux, becomes incompetent when distended by elevated biliary pressure.

Common Organisms:

• Escherichia coli (40-50%)
• Klebsiella pneumoniae (15-20%)
• Enterococcus species (15-20%)
• Bacteroides fragilis (5-10%)
• Polymicrobial in 40-50% of cases [7]

Step 3: Bacterial Proliferation

In the stagnant bile, bacteria proliferate rapidly. The obstructed system becomes a closed-loop infection analogous to empyema of the gallbladder or pyonephrosis. Bacterial endotoxins (lipopolysaccharide from gram-negative organisms) accumulate in high concentrations.

Step 4: Critical Pressure Threshold (20 cm H₂O)

When intra-biliary pressure exceeds 20 cm H₂O, a critical pathophysiological event occurs: the tight junctions between hepatocytes and biliary canaliculi begin to fail. This pressure threshold has been validated in animal models and intraoperative human measurements.

Step 5: Cholangiovenous Reflux (Biliary-Venous Reflux)

Above the critical threshold, bacteria and endotoxins are forced directly from the biliary system into the hepatic venous sinusoids. This is NOT a lymphatic route (which is slower) but direct venous access, explaining the rapid progression to bacteremia and septic shock. [8]

Key Anatomical Point: The porous structure of bile canaliculi, designed for bidirectional exchange under normal pressures, becomes a direct conduit for systemic bacterial dissemination when pressure is pathologically elevated.

Step 6: Kupffer Cell Activation and Failure

The liver's resident macrophages (Kupffer cells) are the first immunological responders. Initially, they phagocytose bacteria and release cytokines (TNF-α, IL-1, IL-6). However, in cholangitis, the bacterial load overwhelms the Kupffer cell capacity, leading to:

• Excessive cytokine release (cytokine storm)
• Hepatocyte injury (contributing to jaundice)
• Systemic inflammatory response syndrome (SIRS)

Step 7: Septic Shock and Multi-Organ Dysfunction

The systemic release of bacterial products and inflammatory mediators leads to:

• Peripheral vasodilation (distributive shock)
• Capillary leak syndrome (third-spacing of fluid)
• Myocardial depression (septic cardiomyopathy)
• Acute kidney injury (often hepatorenal syndrome pattern)
• Altered mental status (hepatic encephalopathy + septic encephalopathy)

This cascade constitutes Reynolds' Pentad and represents the most severe form of cholangitis.

Special Pathophysiological Considerations

Suppurative Cholangitis

In this variant, the bile ducts contain frank pus under pressure. This occurs when:

• Complete obstruction prevents any drainage
• High bacterial loads produce purulent material
• Typically associated with stones or tight strictures

Clinically, these patients are among the sickest and require emergent decompression.

Post-ERCP Cholangitis

Paradoxically, ERCP itself can introduce bacteria or cause incomplete stone extraction, leading to post-procedural cholangitis. Risk factors include:

• Incomplete biliary drainage
• Contrast injection above an obstruction
• Contaminated endoscope (rare with modern reprocessing)

---

4. Clinical Presentation

Diagnostic Triads and Pentad

Charcot's Triad (50-70% of cases)

1. Fever with Rigors: Temperature typically > 38.5°C, often with dramatic shaking chills
2. Right Upper Quadrant Abdominal Pain: Dull, constant, non-colicky (unlike biliary colic)
3. Jaundice: Usually clinically apparent (bilirubin > 50 µmol/L), conjugated hyperbilirubinemia [9]

Clinical Note: The complete triad is present in only 50-70% of cases. Fever is the most common single feature (95%), while jaundice may be delayed or absent in early presentations.

Reynolds' Pentad (less than 10% of cases)

Adds to Charcot's Triad: 4. Hypotension: Systolic BP less than 90 mmHg or requiring vasopressors 5. Altered Mental Status: Confusion, disorientation, or reduced GCS

Prognostic Significance: Reynolds' Pentad indicates suppurative cholangitis with septic shock. Mortality approaches 20-30% even with optimal management. These patients require emergent biliary decompression, typically within 6-12 hours. [10]

Symptom Progression

Early Phase (Hours 0-12):

• Malaise and anorexia
• Low-grade fever
• Vague RUQ discomfort
• Patients may dismiss symptoms initially

Established Phase (Hours 12-48):

• High fever with rigors
• Worsening RUQ pain
• Clinical jaundice appears
• Charcot's Triad fully developed

Severe Phase (Hours 48+):

• Hemodynamic instability
• Oliguria (acute kidney injury)
• Confusion or obtundation
• Multi-organ dysfunction
• Reynolds' Pentad

Atypical Presentations

Elderly Patients

• May present with only confusion and hypotension (sepsis without localizing signs)
• Abdominal pain often minimal or absent
• Higher risk of delayed diagnosis

Immunocompromised

• Blunted fever response
• Rapidly progressive disease
• Higher rates of fungal superinfection (Candida species)

Post-Surgical Patients

• May present weeks to years after biliary surgery
• Stricture formation is a delayed complication

Physical Examination Findings

General Inspection:

• Jaundice (scleral icterus, yellow skin)
• Signs of sepsis (tachycardia, tachypnea, hypotension)
• Altered mental status in severe cases

Abdominal Examination:

• RUQ tenderness (85-90%)
• Murphy's sign often negative (distinguishing from cholecystitis)
• Hepatomegaly (tender liver edge)
• Absence of peritonism unless complicated by perforation (rare)

Important Negative Finding: The absence of guarding and rebound tenderness helps distinguish cholangitis from perforated viscus or severe pancreatitis.

Differential Diagnosis

---

5. Investigations: The Tokyo Criteria (TG18)

Diagnostic Criteria

The TG18 diagnostic criteria require 1 item from EACH of the following categories:

A. Systemic Inflammation

• Fever (> 38°C) and/or rigors
• Laboratory evidence: WCC > 10 × 10⁹/L or less than 4 × 10⁹/L
• CRP elevation > 10 mg/L

B. Cholestasis

• Jaundice (clinical or bilirubin ≥35 µmol/L)
• Abnormal liver enzymes:
  • ALP > 1.5× upper limit of normal
  • GGT > 1.5× upper limit of normal
  • AST/ALT elevation (typically less than 300 U/L, unlike hepatitis)

C. Imaging Evidence

• Biliary dilatation (common bile duct > 6 mm, or > 8 mm if post-cholecystectomy)
• Evidence of etiology: stone, stricture, stent occlusion, mass [11]

Diagnostic Certainty:

• Definite: All three categories fulfilled
• Suspected: Two categories fulfilled

Severity Grading (TG18)

Severity stratification guides the urgency of biliary decompression:

Grade I (Mild)

• Meets diagnostic criteria
• No organ dysfunction
• Responds to initial supportive care

Management: Urgent ERCP within 24-48 hours

Grade II (Moderate)

• Any TWO of the following:
  • WCC > 12 or less than 4 × 10⁹/L
  • Fever ≥39°C
  • Age > 75 years
  • Bilirubin ≥85 µmol/L
  • Albumin less than 30 g/L

Management: Early ERCP within 24 hours

Grade III (Severe)

• Any ONE of the following organ dysfunctions:
  • "Cardiovascular: Hypotension requiring vasopressors"
  • "Neurological: Altered consciousness (GCS less than 15)"
  • "Respiratory: PaO₂/FiO₂ ratio less than 300"
  • "Renal: Creatinine > 177 µmol/L or oliguria"
  • "Hepatic: INR > 1.5"
  • "Hematological: Platelets less than 100 × 10⁹/L"

Management: Emergent biliary drainage within 6-12 hours after resuscitation [12]

Laboratory Investigations

Essential Initial Tests

Full Blood Count:

• Leukocytosis (> 12 × 10⁹/L) or leukopenia (less than 4 × 10⁹/L) in overwhelming sepsis
• Left shift (neutrophilia with band forms)
• Thrombocytopenia in severe sepsis

Liver Function Tests:

• Bilirubin: Typically > 50 µmol/L, predominantly conjugated
• ALP/GGT: Elevated (cholestatic pattern)
• ALT/AST: Mildly elevated (typically less than 300 U/L)
• Albumin: Often reduced in chronic obstruction or malnutrition

Renal Function:

• Creatinine: Elevated in AKI (common complication)
• Urea: Elevated, may be disproportionate (pre-renal component)

Coagulation:

• PT/INR: Prolonged due to impaired vitamin K absorption (cholestasis)
• Important for procedural planning (ERCP requires correction if INR > 1.5)

Inflammatory Markers:

• CRP: Markedly elevated (often > 100 mg/L)
• Procalcitonin: Highly elevated in bacterial infection (> 2 ng/mL indicates severe sepsis)

Sepsis Markers:

• Lactate: > 2 mmol/L indicates tissue hypoperfusion; > 4 mmol/L indicates septic shock
• Blood cultures (×2 sets): Positive in 40-70% of cases

Special Investigations

Tumor Markers (if malignancy suspected):

• CA 19-9: Elevated in cholangiocarcinoma and pancreatic cancer
• CEA: Elevated in colorectal liver metastases
• Note: Both can be falsely elevated in cholestasis alone

Imaging Modalities

1. Transabdominal Ultrasound (First-Line)

Advantages:

• Rapid, bedside availability
• No radiation or contrast
• Good sensitivity for biliary dilatation (80-90%)

Findings in Cholangitis:

• Dilated common bile duct (> 6 mm, or > 8 mm post-cholecystectomy)
• Intraductal stones (echogenic with posterior acoustic shadow)
• Gallbladder stones (associated in 60% of cases)
• Gallbladder wall edema (if concomitant cholecystitis)

Limitations:

• Poor sensitivity for distal CBD stones (25-50%)
• Operator-dependent
• Obscured by bowel gas
• Cannot reliably exclude obstruction if ducts not dilated

Clinical Pearl: A "normal" ultrasound does NOT exclude cholangitis. Early obstruction or intermittent obstruction may not cause ductal dilatation. [13]

2. CT Abdomen with IV Contrast

Indications:

• Suspected complications (abscess, perforation)
• Malignant obstruction suspected
• Ultrasound non-diagnostic

Findings:

• Dilated intrahepatic and extrahepatic bile ducts
• Cause of obstruction (stone appears as hyperdense focus; tumor as mass)
• Liver abscesses (hypoattenuating lesions)
• Pneumobilia (air in biliary tree - may indicate prior sphincterotomy or fistula)

Advantages:

• Excellent for detecting complications
• Defines anatomy for procedural planning
• Identifies alternative diagnoses (pancreatitis, abscess)

Limitations:

• Radiation exposure
• Contrast nephropathy risk (especially with pre-existing AKI)
• Less sensitive than MRCP for biliary detail

3. MRCP (Magnetic Resonance Cholangiopancreatography)

Gold Standard for Non-Invasive Biliary Imaging:

Advantages:

• Excellent sensitivity and specificity for CBD stones (90-95%)
• Defines biliary anatomy completely
• Identifies level and cause of obstruction
• No radiation
• No contrast needed (unless MRCP + MRI liver protocol)

Findings:

• Dilated biliary tree with filling defects (stones)
• Strictures (benign vs. malignant features)
• Choledochal cysts
• Anomalous biliary anatomy

Limitations:

• Not suitable for unstable patients (lengthy procedure)
• Contraindicated with pacemakers/metallic implants (unless MR-compatible)
• Claustrophobia
• Cannot perform therapeutic intervention (unlike ERCP)

Ideal Use: Stable patients (Grade I) where etiology unclear and ERCP may be avoided if no obstruction found.

4. ERCP (Endoscopic Retrograde Cholangiopancreatography)

Unique Feature: Both diagnostic AND therapeutic

Diagnostic Capabilities:

• Direct visualization of bile ducts
• Identification of stones, strictures, tumors
• Biliary brushings/biopsy for cytology

Therapeutic Capabilities:

• Sphincterotomy (cutting the sphincter of Oddi)
• Stone extraction (balloon or basket)
• Biliary stenting (plastic or metal)
• Biliary drainage in malignant obstruction

Indications in Cholangitis:

• Grade II/III: Emergent/urgent therapeutic intervention
• Grade I: After MRCP confirmation of obstruction

Complications:

• Post-ERCP pancreatitis (3-10%)
• Bleeding (1-2%)
• Perforation (less than 1%)
• Recurrent cholangitis (if incomplete drainage)

Success Rate: 85-95% for stone extraction in experienced hands [14]

5. Percutaneous Transhepatic Cholangiography (PTC)

Indications:

• ERCP failure or not feasible (e.g., previous Roux-en-Y gastric bypass, altered anatomy)
• Proximal biliary obstruction (hilar cholangiocarcinoma)
• Failed endoscopic access

Procedure:

• Ultrasound/fluoroscopy-guided puncture of intrahepatic bile duct
• Contrast injection to delineate biliary tree
• External drainage catheter placement

Advantages:

• Effective when ERCP impossible
• Allows drainage of isolated segments

Complications:

• Bile leak (5-10%)
• Bleeding (hemo-bile)
• Catheter dislodgement
• Patient discomfort (external drain)

---

6. Management: The Resuscitation-Drainage Paradigm

Management of cholangitis is based on three parallel pillars:

1. Resuscitation (treating sepsis)
2. Biliary decompression (removing the source)
3. Antibiotic therapy (controlling infection)

The relative urgency of each pillar is determined by the TG18 severity grade.

Phase 1: Immediate Resuscitation (Sepsis Six)

In any patient with suspected cholangitis and systemic toxicity, initiate the "Sepsis Six" within the first hour:

1. High-flow Oxygen: Target SpO₂ > 94%
2. Blood Cultures: Two sets (before antibiotics if possible)
3. IV Antibiotics: Broad-spectrum, biliary-penetrating (see below)
4. IV Fluids: Crystalloid resuscitation (Hartmann's or 0.9% saline), 500 mL boluses titrated to BP and urine output
5. Lactate Measurement: Arterial or venous lactate to assess tissue perfusion
6. Urine Output Monitoring: Catheterize if Grade II/III to monitor hourly urine output

Additional Critical Care:

• Grade III patients: Consider ICU admission, invasive monitoring, vasopressor support
• Correct coagulopathy: Vitamin K 10 mg IV, FFP if INR > 1.5 and intervention planned

Phase 2: Antibiotic Therapy

Empirical Antibiotic Selection

First-Line (Community-Acquired):

• Piperacillin-Tazobactam 4.5 g IV every 6-8 hours
  • Excellent biliary penetration
  • Covers gram-negatives, anaerobes, and Enterococcus

Alternative Regimens:

• Ceftriaxone 2 g IV daily + Metronidazole 500 mg IV every 8 hours
• Ciprofloxacin 400 mg IV every 12 hours + Metronidazole 500 mg IV every 8 hours

Healthcare-Associated or Severe Sepsis:

• Meropenem 1 g IV every 8 hours (if suspicion of ESBL-producing organisms)
• Consider adding Vancomycin 15-20 mg/kg IV if risk of MRSA or VRE

Antifungal Coverage:

• Add Fluconazole 400 mg IV daily if:
  • Immunocompromised
  • Prolonged hospitalization
  • Recent broad-spectrum antibiotic use
  • Biliary stent in situ [15]

Antibiotic Duration

• Uncomplicated: 5-7 days after successful drainage
• Bacteremia: 7-10 days
• Liver abscess: 14-21 days with drainage

Pharmacokinetic Considerations

Biliary Penetration: Not all antibiotics achieve adequate biliary concentrations. The following have excellent biliary penetration:

• Piperacillin-tazobactam
• Ampicillin
• Ceftriaxone
• Ciprofloxacin

Poor Biliary Penetration:

• Aminoglycosides (gentamicin) - avoid as monotherapy
• Vancomycin - poor biliary levels despite excellent serum levels

Phase 3: Biliary Decompression - Timing and Modality

The Definitive Treatment: Decompression is MORE important than antibiotics in cholangitis. Antibiotics buy time, but drainage saves lives.

Timing Based on TG18 Severity

Critical Evidence: The Lai et al. landmark trial (1992) demonstrated that emergency ERCP within 24 hours reduced mortality from 32% to 10% in severe cholangitis compared to delayed or surgical drainage. [16]

ERCP - The Gold Standard

Procedure Overview:

1. Patient sedation (conscious sedation or general anesthesia)
2. Duodenoscope insertion to second part of duodenum
3. Cannulation of ampulla of Vater
4. Contrast injection (cholangiogram)
5. Sphincterotomy (electrocautery incision of sphincter)
6. Stone extraction (basket or balloon)
7. Stent placement (if stricture or incomplete clearance)

Success Rates:

• Cannulation: 90-95%
• Stone extraction: 85-90% in single session
• Complication rate: 5-10% overall

Post-ERCP Care:

• NPO for 4 hours
• Monitor for complications (pancreatitis, bleeding, perforation)
• Repeat liver function tests at 24 hours
• Consider interval cholecystectomy if gallbladder in situ

PTC - When ERCP Fails

Indications:

• Failed ERCP cannulation
• Altered anatomy (Roux-en-Y, Billroth II)
• Proximal biliary obstruction
• Patient too unstable for endoscopy

Technique:

• Percutaneous ultrasound or fluoroscopy-guided puncture
• Contrast injection to visualize biliary tree
• Placement of external drainage catheter
• Can convert to internal-external drainage later

Outcomes:

• Success rate: 95-98%
• Allows immediate decompression even in difficult anatomy

Surgical Drainage - Last Resort

Indications (Rare):

• Failed ERCP and PTC
• Perforated bile duct
• Concomitant pathology requiring laparotomy (e.g., perforated viscus)

Procedures:

• T-tube insertion into CBD
• Choledochotomy with stone extraction
• Hepaticojejunostomy for complex strictures

Outcomes:

• Higher morbidity and mortality than endoscopic/percutaneous routes
• Mortality 10-20% in emergency setting (vs. 5% for ERCP)

Phase 4: Definitive Management of Underlying Cause

Choledocholithiasis

• ERCP with sphincterotomy and stone extraction
• Interval laparoscopic cholecystectomy (if gallbladder present) within 2-6 weeks to prevent recurrence

Benign Biliary Stricture

• Endoscopic dilation and stenting
• May require multiple sessions
• Long-term stent placement with regular exchanges

Malignant Obstruction

• Palliative stenting (metal stent preferred for longer patency)
• Oncological assessment for resectability
• Chemotherapy/radiotherapy as per tumor type

Biliary Stent Occlusion

• Stent removal and replacement
• Consider metal stent if recurrent occlusion

---

7. Prognosis and Complications

Mortality

Overall Mortality: 5-10% in modern series
Severe Cholangitis (Grade III): 20-30%
Delayed Drainage (> 48h): Mortality doubles

Independent Predictors of Mortality:

• Age > 75 years
• Acute kidney injury
• Albumin less than 30 g/L
• Platelet count less than 150 × 10⁹/L
• Bacteremia with resistant organisms

Acute Complications

1. Septic Shock

• Most common cause of death
• Requires ICU admission, vasopressors, invasive monitoring
• Mortality 30-40% despite optimal care

2. Acute Kidney Injury

• Multifactorial: sepsis, hypotension, nephrotoxic drugs
• May require renal replacement therapy
• Associated with significantly increased mortality

3. Liver Abscess

• Complicates 5-10% of cases
• Presents with persistent fever despite drainage and antibiotics
• Requires percutaneous or surgical drainage

4. Post-ERCP Pancreatitis

• Occurs in 3-10% of ERCP procedures
• Typically mild, but can be severe
• Prophylactic rectal NSAIDs reduce risk

5. Biliary Perforation

• Rare but catastrophic
• Presents with peritonitis
• Requires emergency surgical intervention

Long-Term Complications

1. Recurrent Cholangitis

• Risk 10-20% within 2 years if incomplete stone clearance
• Higher risk with biliary strictures, stents, or PSC

2. Secondary Biliary Cirrhosis

• Chronic obstruction (> 6 months) leads to irreversible fibrosis
• Presents with progressive jaundice, pruritus, portal hypertension

3. Cholangiocarcinoma

• Chronic inflammation (PSC, recurrent pyogenic cholangitis) increases risk
• Surveillance with imaging and CA 19-9 in high-risk patients

Prognostic Scores

Several scoring systems predict outcomes:

APACHE II Score:

• General critical care scoring

• 15 associated with high mortality

SOFA Score:

• Sequential Organ Failure Assessment
• Tracks multi-organ dysfunction
• Rising score indicates poor prognosis

Charlson Comorbidity Index:

• Age and comorbidities predict baseline risk

---

8. Prevention

Primary Prevention (Preventing First Episode)

1. Early Cholecystectomy for Symptomatic Gallstones

• Prevents migration of stones to CBD
• Laparoscopic cholecystectomy has low morbidity

2. Prophylactic Antibiotics During ERCP

• Single dose of ceftriaxone or ciprofloxacin
• Reduces post-ERCP cholangitis from 3% to less than 1%

3. Complete Biliary Drainage

• Ensure no residual stones or debris
• Adequate stent caliber for malignant strictures

Secondary Prevention (Preventing Recurrence)

1. Interval Cholecystectomy

• Perform within 2-6 weeks after ERCP for gallstone cholangitis
• Reduces recurrence from 30% to less than 5%

2. Regular Stent Exchange

• Plastic stents should be exchanged every 3-6 months
• Metal stents have longer patency (6-12 months)

3. Treatment of Underlying Conditions

• PSC: Ursodeoxycholic acid, surveillance for dominant strictures
• Parasitic infections: Anti-parasitic therapy (praziquantel)

---

9. Special Populations

Elderly Patients (> 75 years)

Challenges:

• Atypical presentations (confusion without fever)
• Multiple comorbidities increase procedural risk
• Higher baseline mortality

Management Considerations:

• Lower threshold for ICU admission
• Careful fluid balance (risk of heart failure)
• Geriatric assessment for post-procedure rehabilitation

Immunocompromised

Includes:

• Chemotherapy patients
• Solid organ transplant recipients
• HIV/AIDS
• Chronic corticosteroid use

Specific Issues:

• Broader microbial spectrum (fungi, atypical bacteria)
• Blunted inflammatory response (may have minimal fever/WCC)
• Higher mortality

Antibiotic Modifications:

• Add antifungal coverage empirically
• Consider antiviral coverage in transplant recipients
• Prolonged antibiotic duration

Pregnancy

Rare but Important:

• Second trimester is safest for ERCP if required
• Avoid radiation where possible (use ultrasound/MRI)
• Multidisciplinary care (obstetrics, gastroenterology, anesthesia)

ERCP in Pregnancy:

• Can be performed safely with lead shielding
• Minimize fluoroscopy time
• Consider sphincterotomy without cholangiogram

---

10. Exam-Focused Content

Single Best Answer (SBA) Questions

Question 1

A 75-year-old female presents with fever (39.2°C), jaundice, and RUQ pain. Her BP is 85/50 mmHg and she is confused (GCS 13). Blood tests show: Bilirubin 95 µmol/L, WCC 22 × 10⁹/L, Creatinine 210 µmol/L, Lactate 5.2 mmol/L. Ultrasound shows a dilated CBD (12 mm) with multiple stones. What is the most appropriate next step after initiating the Sepsis Six protocol and IV antibiotics?

A) Arrange urgent MRCP within 24 hours
B) Perform bedside ultrasound to reassess
C) Emergent biliary drainage via ERCP within 6-12 hours
D) Laparoscopic cholecystectomy
E) CT abdomen with IV contrast

Answer: C. This patient has Reynolds' Pentad (Charcot's Triad + Hypotension + Confusion), indicating TG18 Grade III (Severe) cholangitis. She has multi-organ dysfunction (cardiovascular, neurological, renal). The definitive management is emergent biliary decompression via ERCP within 6-12 hours after initial resuscitation. Delays in drainage significantly increase mortality. MRCP (option A) would delay intervention. Surgery (option D) has higher mortality than ERCP in emergency settings.

Question 2

What is the physiological threshold pressure in the biliary tree above which "Cholangiovenous Reflux" occurs, allowing bacteria to enter the systemic circulation?

A) 5 cm H₂O
B) 10 cm H₂O
C) 15 cm H₂O
D) 20 cm H₂O
E) 30 cm H₂O

Answer: D. Once intra-biliary pressure exceeds 20 cm H₂O, the tight junctions between hepatocytes and biliary canaliculi fail, allowing direct translocation of bacteria and endotoxins from bile into the hepatic venous sinusoids. This mechanism explains the rapid progression to bacteremia and septic shock in cholangitis. Normal biliary pressure is 7-14 cm H₂O.

Question 3

A 68-year-old man with suspected cholangitis has a transabdominal ultrasound showing a common bile duct diameter of 5 mm with no visible stones. Which of the following is the most appropriate interpretation?

A) Cholangitis is excluded; look for alternative diagnosis
B) The CBD is normal size; no further biliary imaging needed
C) Ultrasound has poor sensitivity for distal CBD stones; further imaging with MRCP is warranted
D) The patient needs immediate ERCP regardless of ultrasound findings
E) Repeat ultrasound in 24 hours

Answer: C. A normal-sized CBD on ultrasound does NOT exclude cholangitis. Ultrasound has poor sensitivity (25-50%) for distal common bile duct stones, especially small stones or those obscured by bowel gas. Early obstruction may not cause ductal dilatation. In a patient with clinical features of cholangitis (Charcot's Triad, cholestatic LFTs, systemic inflammation), further imaging with MRCP or proceeding directly to ERCP is appropriate. The clinical picture takes precedence over a single negative imaging modality. [17]

Viva Voce Scenarios

Scenario 1: The "Normal" Ultrasound Paradox

Examiner: "A 65-year-old woman presents with fever (38.8°C), RUQ pain, and jaundice. Her bilirubin is 78 µmol/L, ALP 450 U/L, WCC 15 × 10⁹/L. Ultrasound shows a CBD of 5 mm with no stones visible. Your registrar suggests discharging her with oral antibiotics for 'viral illness.' What is your response?"

Model Answer: "I would not discharge this patient. She meets the Tokyo Guidelines (TG18) criteria for acute cholangitis:

• Category A (Systemic Inflammation): Fever and leukocytosis
• Category B (Cholestasis): Jaundice and elevated ALP
• Category C would require imaging evidence, but ultrasound has poor sensitivity for distal CBD stones (25-50%)

The absence of CBD dilatation on ultrasound does NOT exclude cholangitis. Ducts may not be dilated in early or intermittent obstruction. I would:

1. Admit the patient
2. Continue IV antibiotics with biliary penetration (piperacillin-tazobactam)
3. Arrange MRCP to identify the cause of obstruction
4. Prepare for urgent ERCP within 24-48 hours if obstruction confirmed

Discharging this patient risks progression to severe cholangitis (Grade III) with septic shock, which has 20-30% mortality."

Scenario 2: Timing of Biliary Drainage

Examiner: "Walk me through how the Tokyo Guidelines determine the urgency of biliary drainage in cholangitis."

Model Answer: "The Tokyo Guidelines 2018 stratify cholangitis into three severity grades, which directly dictate the timing of biliary decompression:

Grade I (Mild):

• Definition: Meets diagnostic criteria but no organ dysfunction
• Timing: Urgent drainage within 24-48 hours
• Rationale: Patients typically respond to antibiotics initially, but drainage is needed to prevent relapse and clear the source

Grade II (Moderate):

• Definition: Any TWO of: WCC > 12 or less than 4, fever ≥39°C, age > 75, bilirubin ≥85 µmol/L, or albumin less than 30 g/L
• Timing: Early drainage within 24 hours
• Rationale: Higher risk of progression to organ dysfunction; antibiotics alone have higher failure rates

Grade III (Severe):

• Definition: ANY ONE organ dysfunction:
  • Cardiovascular (hypotension/shock)
  • Neurological (altered consciousness)
  • Respiratory (PaO₂/FiO₂ less than 300)
  • Renal (Creatinine > 177 µmol/L)
  • Hepatic (INR > 1.5)
  • Hematological (Platelets less than 100)
• Timing: Emergent drainage within 6-12 hours after initial resuscitation
• Rationale: This is suppurative cholangitis with pus under pressure. Without mechanical drainage, mortality is 30-50%. Antibiotics alone cannot sterilize the obstructed biliary system.

The landmark trial by Lai et al. (1992) established that emergency ERCP within 24 hours reduced mortality from 32% to 10% in severe cholangitis compared to delayed drainage." [18]

Scenario 3: Antibiotic Selection

Examiner: "Why is piperacillin-tazobactam preferred over gentamicin for empirical treatment of cholangitis?"

Model Answer: "The key factor is biliary penetration. Not all antibiotics achieve therapeutic concentrations in bile, even with adequate serum levels.

Piperacillin-Tazobactam:

• Excellent biliary excretion and penetration
• Broad-spectrum: covers gram-negative organisms (E. coli, Klebsiella), anaerobes (Bacteroides), and Enterococcus
• Bactericidal mechanism ideal for septic patients

Gentamicin (Aminoglycosides):

• Poor biliary penetration despite excellent serum levels
• Primarily renally excreted
• Nephrotoxic - problematic in cholangitis patients who often have AKI
• Should NOT be used as monotherapy for cholangitis

Other antibiotics with good biliary penetration include:

• Ceftriaxone
• Ciprofloxacin
• Ampicillin

In healthcare-associated or severe sepsis with risk of ESBL-producing organisms, I would escalate to meropenem, which also has excellent biliary penetration."

---

11. Clinical Pearls and Pitfalls

Pearls

1. The "Unhappy Jaundice": Painless jaundice suggests malignant obstruction; painful jaundice suggests cholangitis or choledocholithiasis.

2. Lactate Over Temperature: In elderly or immunocompromised patients, elevated lactate is a more reliable marker of severe infection than fever.

3. Coagulopathy is Obstructive: Prolonged PT/INR in cholestasis is due to impaired vitamin K absorption, not hepatocellular failure. It corrects rapidly with vitamin K.

4. Post-ERCP Amylase: Check amylase 4 hours post-ERCP to screen for post-ERCP pancreatitis (complicates 3-10% of cases).

5. Charcot's Incompleteness: Only 50-70% have the complete triad. Fever is the most consistent finding (95%).

Pitfalls

1. Assuming Normal USS = No Cholangitis: Ultrasound has poor sensitivity for distal CBD stones. Clinical suspicion should drive further imaging.

2. Delaying ERCP for MRCP: In Grade III patients, do NOT delay drainage for non-urgent imaging. ERCP is both diagnostic and therapeutic.

3. Antibiotics Alone in Grade III: Severe cholangitis cannot be cured with antibiotics alone. Mechanical drainage is the definitive treatment.

4. Ignoring Post-ERCP Surveillance: Patients with gallbladder in situ have 30% risk of recurrent biliary events without interval cholecystectomy.

5. Undertreating the Elderly: Elderly patients with "mild confusion" may have full-blown Reynolds' Pentad. Low threshold for ICU admission.

---

12. Patient Explanation (Layperson Level)

"Ascending Cholangitis is a serious infection of the tubes that drain bile from your liver, called bile ducts. Normally, bile flows from the liver into the intestine to help digest food. If a gallstone or blockage gets stuck in the main drainage pipe (the common bile duct), the bile backs up, like a blocked sink. This stagnant bile becomes infected with bacteria that normally live in your intestine.

Because the liver has direct connections to your bloodstream, the infection can quickly spread throughout your body, causing a very serious condition called sepsis or blood poisoning. The classic signs are high fever with shaking chills, yellowing of your skin and eyes (jaundice), and abdominal pain on the right side.

This is a medical emergency. We treat it with two main steps:

1. Strong intravenous antibiotics to fight the infection
2. Urgent drainage procedure (ERCP) - a camera scope passed down through your mouth into your intestine to remove the blockage and allow bile to flow freely again

Think of it like a plumbing emergency: antibiotics help control the infection, but we must physically clear the blockage to fully solve the problem. Most patients recover well with prompt treatment, but delays can be life-threatening."

---

13. References

1. Kiriyama S, Kozaka K, Takada T, et al. Tokyo Guidelines 2018: diagnostic criteria and severity grading of acute cholangitis (with videos). J Hepatobiliary Pancreat Sci. 2018;25(1):17-30. PMID: 29032610. DOI: 10.1002/jhbp.512

2. Miura F, Okamoto K, Takada T, et al. Tokyo Guidelines 2018: initial management of acute biliary infection and flowchart for acute cholangitis. J Hepatobiliary Pancreat Sci. 2018;25(1):31-40. PMID: 29090868. DOI: 10.1002/jhbp.509

3. Mayumi T, Okamoto K, Takada T, et al. Tokyo Guidelines 2018: management bundles for acute cholangitis and cholecystitis. J Hepatobiliary Pancreat Sci. 2018;25(1):96-100. PMID: 28941329. DOI: 10.1002/jhbp.519

4. Williams EJ, Green J, Beckingham I, et al. Guidelines on the management of common bile duct stones (CBDS). Gut. 2008;57(7):1004-1021. PMID: 18321943. DOI: 10.1136/gut.2007.121657

5. Mosler P. Diagnosis and management of acute cholangitis. Curr Gastroenterol Rep. 2011;13(2):166-172. PMID: 21222060. DOI: 10.1007/s11894-010-0171-7

6. Lai EC, Mok FP, Tan ES, et al. Endoscopic biliary drainage for severe acute cholangitis. N Engl J Med. 1992;326(24):1582-1586. PMID: 1584258. DOI: 10.1056/NEJM199206113262401

7. Sung YK, Lee JK, Lee KH, et al. The clinical features and prognosis of acute cholangitis in patients 60 years of age and above. Korean J Gastroenterol. 2012;59(4):283-288. PMID: 22695081. DOI: 10.4166/kjg.2012.59.4.283

8. Clements WD, Erwin P, McCaigue MD, et al. Biliary decompression in obstructive jaundice reduces hepatic neutrophil accumulation and cytokine production. Gut. 1996;38(6):925-931. PMID: 8984034. DOI: 10.1136/gut.38.6.925

9. Lee JG. Diagnosis and management of acute cholangitis. Nat Rev Gastroenterol Hepatol. 2009;6(9):533-541. PMID: 19652653. DOI: 10.1038/nrgastro.2009.126

10. Gigot J, Leese T, Dereme T, et al. Acute cholangitis: multivariate analysis of risk factors. Ann Surg. 1989;209(4):435-438. PMID: 2930289. DOI: 10.1097/00000658-198904000-00008

11. Wada K, Takada T, Kawarada Y, et al. Diagnostic criteria and severity assessment of acute cholangitis: Tokyo Guidelines. J Hepatobiliary Pancreat Surg. 2007;14(1):52-58. PMID: 17252297. DOI: 10.1007/s00534-006-1156-7

12. Kimura Y, Takada T, Kawarada Y, et al. Definitions, pathophysiology, and epidemiology of acute cholangitis and cholecystitis: Tokyo Guidelines. J Hepatobiliary Pancreat Surg. 2007;14(1):15-26. PMID: 17252293. DOI: 10.1007/s00534-006-1152-y

13. Prat F, Amouyal G, Amouyal P, et al. Prospective controlled study of endoscopic ultrasonography and endoscopic retrograde cholangiography in patients with suspected common bile duct lithiasis. Lancet. 1996;347(8994):75-79. PMID: 8538345. DOI: 10.1016/s0140-6736(96)90209-3

14. Freeman ML, Nelson DB, Sherman S, et al. Complications of endoscopic biliary sphincterotomy. N Engl J Med. 1996;335(13):909-918. PMID: 8782497. DOI: 10.1056/NEJM199609263351301

15. Gomi H, Solomkin JS, Takada T, et al. Tokyo Guidelines 2018: antimicrobial therapy for acute cholangitis and cholecystitis. J Hepatobiliary Pancreat Sci. 2018;25(1):3-16. PMID: 29090866. DOI: 10.1002/jhbp.518

16. Hui CK, Lai KC, Yuen MF, et al. Does withholding antibiotics reduce the incidence of cholangitis after endoscopic retrograde cholangiopancreatography? A randomized controlled trial. Aliment Pharmacol Ther. 2002;16(5):929-936. PMID: 11966499. DOI: 10.1046/j.1365-2036.2002.01243.x

17. Tse F, Liu L, Barkun AN, et al. EUS: a meta-analysis of test performance in suspected choledocholithiasis. Gastrointest Endosc. 2008;67(2):235-244. PMID: 18226685. DOI: 10.1016/j.gie.2007.09.047

18. van Lent AU, Bartelsman JF, Tytgat GN, et al. Duration of antibacterial treatment for cholangitis after successful endoscopic drainage of the biliary tract. Gastrointest Endosc. 2002;55(4):518-522. PMID: 11923764. DOI: 10.1067/mge.2002.122333

---

Last Updated: 2026-01-06 | MedVellum Editorial Team
Evidence Level: High | 18 PubMed Citations
Target: MRCP, FRACP, MRCS, Emergency Medicine Postgraduate Examinations